Idiopathic Pulmonary Fibrosis (IPF) Market Size Share Revenue And Structure Forecast To 2031 | Genentech, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG. In

The Global Idiopathic Pulmonary Fibrosis (IPF) market held a market value of USD 2,073.9 Million in 2021 and is forecasted to reach USD 4,298.8 Million by the year 2030. The market is anticipated to register a CAGR of 9.4% over the projected period.

Request To Download Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=ARS248

Idiopathic Pulmonary Fibrosis (IPF) is one of the most common types of pulmonary fibrosis, which causes scarring or fibrosis in the lungs. This makes it difficult for a person to breath. Growing geriatric population, increase in smokers? population, and favourable support through funding for the pulmonary fibrosis research is anticipated to boost the market growth. Despite the driving factors, high treatment cost are expected to hinder the market growth during the forecast period.

Growth Influencers:

Growing geriatric population
Geriatric population is more likely to suffer from idiopathic pulmonary fibrosis (IPF), which is likely to boost the market growth. According to the WHO, the geriatric population is expected to nearly double from 12% to 22% between 2015 and 2050. Also, according to Medscape, as of July 2021, approximately two third of IPF patients are above the age of 60 years. It also stated that in the U.S., the incidence rate of IPF in people aged 18 to 34 years is around 0.4-1.2 cases per 100,000 people and in people aged 75 years or older is ranged between 27.1-76.4 cases per 100,000 people. Therefore, growing geriatric population is expected to fuel the market growth over the projected period.

Increase in smokers? population

According to BioNews, Inc., as of October 2021, current smokers are at higher risk of IPF as compared to former smokers. The exact cause of IPF is unknown, however smoking cigarettes is most probably the most well-established risk factor for IPF. The source also stated that, at the end of 2016, in a study, 27.2% of IPF patients were current smokers, 23.2% were former smokers, and 49.6% were never-smokers. Therefore, the growing smokers? population is expected to boost the market growth.

Segments Overview:

The Global Idiopathic Pulmonary Fibrosis (IPF) market is segmented based on therapy.
By Therapy,
? Esbriet (Pirfenidone)
? Ofev (Nintedanib)
? Tipelukast
? Pamrevlumab
? KD025
? PRM 151
? GKT831
? Other IPF Therapy

Download Free Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=ARS248

The Esbriet (Pirfenidone) segment is expected to account for the highest share of 30% in the U.S. market in 2021. This is because it has received the label of ?conditional recommendation for IPF treatment?. The tipelukast segment is anticipated to grow at a CAGR of 8.7% in the UK market, owing to the growing number of players involved in the development of tipelukast.

Regional Overview

Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.

The U.S. is estimated to account for the largest market share of over 60% in 2021 owing to the growing research activities for IPF and presence of a significant infrastructure for the development of innovative therapies.
EU5 is further divided into the UK, France, Germany, Spain, and Italy. The UK is expected to hold an opportunity of USD 232.2 million during 2021 to 2030. This is owing to the increasing prevalence of idiopathic pulmonary fibrosis in the country.
The prevalent population of IPF is usually based on the severity, gender, and age. In Japan, the prevalent population was 18.849. Similarly, in the U.S., the prevalent population of IPF, based on severity was 74,230 in 2021 and 1,27,397 in 2030 based on radiological markers of disease severity and 43,973 in 2021, based on the composite measures of disease severity.

Competitive Landscape

Currently marketed products include Esbriet (Pirfenidone) by Genentech, Inc. and Ofev by Boehringer Ingelheim Pharma GmbH & Co. KG. In March 2020, Esbriet received U.S. FDA?s Breakthrough Therapy Designation for adults suffering from unclassifiable interstitial lung disease. Similarly, in March 2020, Ofev by Boehringer Ingelheim GmbH received U.S. FDA approval for use as a first treatment for people suffering from chronic fibrosing interstitial lung diseases (ILDs). Also, in October 2021, Ofev was recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adult patients suffering from chronic fibrosis ILD with a progressive phenotype, PF-ILD.

The Global Idiopathic Pulmonary Fibrosis (IPF) market report provides insights on the below pointers:

? Market Penetration: Provides comprehensive information on the market offered by the prominent players
? Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
? Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
? Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Global Idiopathic Pulmonary Fibrosis (IPF) market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.

To Get More Business Strategies For Request Sample Report:-https://reportocean.com/industry-verticals/sample-request?report_id=ARS248

? Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
? Current Treatment Practices: ATS//ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
? Organizations contributing towards IPF: Pulmonary Fibrosis Foundation (PFF), National Organization for Rare Disorder, Second Wind Lung Transplant Association, Inc., Other Organizations
? Case Reports: Idiopathic Pulmonary Fibrosis: A Case Discussion in the US, Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A Case Report of Europe, Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis ? A Japanese Case Report
? Marketed Products- Esbriet (Pirfenidone): Genentech, Inc. (Drug Description, Regulatory Milestones, Advantages & Disadvantages, Safety and Efficacy, Side Effects of Esbriet, Product Profile); Ofev: Boehringer Ingelheim Pharma GmbH and Co. Kg
? Emerging Therapies: Tipelukast: MediciNova (Drug Description, Clinical Development, Clinical Trial Information, Primary Outcomes, Secondary Outcomes, Product Profile, Pamrevlumab: FibroGen, KD025: Kadmon Corporation, LLC, Promedior: PRM-151); GKT831: Genkyotex
? Other Promising Candidates: CC-90001: Celgene Corporation, LT-1001: Beijing Tide Pharmaceutical, LT-1002: ChongKun DangPharmaceutical, BG00011: BiogenInc, PBI4050: ProMetic LifeSciences, TD139: Galecto Biotech, VAY736: Novartis

The Global Idiopathic Pulmonary Fibrosis (IPF) market report answers questions such as:

? What is the market size and forecast of the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What are the inhibiting factors and impact of COVID-19 on the Global Idiopathic Pulmonary Fibrosis (IPF) Market during the assessment period?
? Which are the products/segments/applications/areas to invest in over the assessment period in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What is the competitive strategic window for opportunities in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What are the technology trends and regulatory frameworks in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What is the market share of the leading players in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What modes and strategic moves are considered favorable for entering the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
? What are the unmet needs in IPF Market?

Request Full Report- https://reportocean.com/industry-verticals/sample-request?report_id=ARS248

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean is the world's leading research company, known for its informative research reports. We are committed to providing our clients with both quantitative and qualitative research results. As a part of our global network and comprehensive industry coverage, we offer in-depth knowledge, allowing informed and strategic business conclusions to report. We utilize the most recent technology and analysis tools along with our own unique research models and years of expertise, which assist us to create necessary details and facts that exceed expectations.

Get in Touch with Us:
Report Ocean:
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 - UNITED STATES
Tel:+1888 212 3539 (US - TOLL FREE)
Website:https://reportocean.com

This release was published on openPR.